Gene Immunotherapy for Non-Small Cell Lung Cancer

  • John J. J. NemunaitisEmail author
Part of the Methods in Molecular Biology™ book series (MIMB, volume 542)


Historically, limited results have been observed with immunity in non-small cell lung cancer (NSCLC). In the last 5 years, however, several immune-stimulating products have demonstrated enhancement of tumor antigen recognition through activation of dendritic cell-involved processes. Moreover, clinical benefit has been demonstrated in subsets of patients, justifying ongoing phase III investigation. Results of key gene immunotherapies being tested in NSCLC are reviewed. Preliminary results in advanced NSCLC suggest evidence of well-tolerated immune activation with suggested evidence of clinical benefit with respect to survival and response.

Key Words

Gene immunotherapy non-small cell lung cancer 


  1. 1.
    Alexandroff AB, Jackson AM, O'Donnell MA, James K. BCG immunotherapy of bladder cancer: 20 years on. Lancet 1999;353(9165):1689–94.PubMedGoogle Scholar
  2. 2.
    Coppin C, Porzsolt F, Awa A, Kumpf J, Coldman A, Wilt T. Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev 2005(1):CD001425.Google Scholar
  3. 3.
    Eton O, Legha SS, Bedikian AY, et al. Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial. J Clin Oncol 2002;20(8):2045–52.PubMedGoogle Scholar
  4. 4.
    Kaufman HL, Wang W, Manola J, et al. Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): a trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2004;22(11):2122–32.PubMedGoogle Scholar
  5. 5.
    Kwak LW. Translational development of active immunotherapy for hematologic malignancies. Semin Oncol 2003;30(3 Suppl 8):17–22.PubMedGoogle Scholar
  6. 6.
    Quan WD, Jr., Dean GE, Spears L, et al. Active specific immunotherapy of metastatic melanoma with an antiidiotype vaccine: a phase I/II trial of I-Mel-2 plus SAF-m. J Clin Oncol 1997;15(5):2103–10.PubMedGoogle Scholar
  7. 7.
    Woo EY, Yeh H, Chu CS, et al. Cutting edge: Regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J Immunol 2002;168(9):4272–6.PubMedGoogle Scholar
  8. 8.
    Dohadwala M, Luo J, Zhu L, et al. Non-small cell lung cancer cyclooxygenase-2-dependent invasion is mediated by CD44. J Biol Chem 2001;276(24):20809–12.PubMedGoogle Scholar
  9. 9.
    Neuner A, Schindel M, Wildenberg U, Muley T, Lahm H, Fischer JR. Prognostic significance of cytokine modulation in non-small cell lung cancer. Int J Cancer 2002;101(3):287–92.PubMedGoogle Scholar
  10. 10.
    Fontana A, Frei K, Bodmer S, et al. Transforming growth factor-beta inhibits the generation of cytotoxic T cells in virus-infected mice. J Immunol 1989;143(10):3230–4.PubMedGoogle Scholar
  11. 11.
    Rook AH, Kehrl JH, Wakefield LM, et al. Effects of transforming growth factor beta on the functions of natural killer cells: depressed cytolytic activity and blunting of interferon responsiveness. J Immunol 1986;136(10):3916–20.PubMedGoogle Scholar
  12. 12.
    Tsunawaki S, Sporn M, Ding A, Nathan C. Deactivation of macrophages by transforming growth factor-beta. Nature 1988;334(6179):260–2.PubMedGoogle Scholar
  13. 13.
    Suzuki K, Nagai K, Yoshida J, et al. Prognostic factors in clinical stage I non-small cell lung cancer. Ann Thorac Surg 1999;67(4):927–32.PubMedGoogle Scholar
  14. 14.
    Yano T, Yokoyama H, Inoue T, Asoh H, Tayama K, Ichinose Y. Surgical results and prognostic factors of pathologic N1 disease in non-small-cell carcinoma of the lung. Significance of N1 level: lobar or hilar nodes. J Thorac Cardiovasc Surg 1994;107(6):1398–402.PubMedGoogle Scholar
  15. 15.
    Caldarella A, Crocetti E, Comin CE, Janni A, Pegna AL, Paci E. Prognostic variability among nonsmall cell lung cancer patients with pathologic N1 lymph node involvement. Epidemiological figures with strong clinical implications. Cancer 2006;107(4):793–8.PubMedGoogle Scholar
  16. 16.
    Rosell R, Gomez-Codina J, Camps C, et al. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. N Engl J Med 1994;330(3):153–8.PubMedGoogle Scholar
  17. 17.
    Roth JA, Fossella F, Komaki R, et al. A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. Journal of the National Cancer Institute 1994;86(9):673–80.PubMedGoogle Scholar
  18. 18.
    Jassem J, Skokowski J, Dziadziuszko R, et al. Results of surgical treatment of non-small cell lung cancer: validation of the new postoperative pathologic TNM classification. J Thorac Cardiovasc Surg 2000;119(6):1141–6.PubMedGoogle Scholar
  19. 19.
    Leong SS, Rocha Lima CM, Sherman CA, Green MR. The 1997 International Staging System for non-small cell lung cancer: have all the issues been addressed? Chest 1999;115(1):242–8.PubMedGoogle Scholar
  20. 20.
    Fry WA, Phillips JL, Menck HR. Ten-year survey of lung cancer treatment and survival in hospitals in the United States: a national cancer data base report. Cancer 1999;86(9):1867–76.PubMedGoogle Scholar
  21. 21.
    Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. New England J Med 2002;346(2):92–8.Google Scholar
  22. 22.
    Duda DG, Jain RK, Willett CG. Antiangiogenics: the potential role of integrating this novel treatment modality with chemoradiation for solid cancers. J Clin Oncol 2007;25(26):4033–42.PubMedGoogle Scholar
  23. 23.
    Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355(24):2542–50.PubMedGoogle Scholar
  24. 24.
    Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000;18(10):2095–103.PubMedGoogle Scholar
  25. 25.
    Fossella FV, DeVore R, Kerr RN, et al.Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol 2000;18(12):2354–62.PubMedGoogle Scholar
  26. 26.
    Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004;22(9):1589–97.PubMedGoogle Scholar
  27. 27.
    Tsao MS, Sakurada A, Cutz JC, et al. Erlotinib in lung cancer - molecular and clinical predictors of outcome. New Engl J Med 2005;353(2):133–44.PubMedGoogle Scholar
  28. 28.
    Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. New Engl J Med 2005;353(2):123–32.PubMedGoogle Scholar
  29. 29.
    Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003;290(16):2149–58.PubMedGoogle Scholar
  30. 30.
    Prien RTMM. Immunity to methyl cholanthrene induced sarcomas. J Natl Cancer Inst 1957;18:769–78.Google Scholar
  31. 31.
    Kripke ML. Antigenicity of murine skin tumors induced by ultraviolet light. J Natl Cancer Inst 1974;53(5):1333–6.PubMedGoogle Scholar
  32. 32.
    Yang JC, Perry-Lalley D, Rosenberg SA. An improved method for growing murine tumor-infiltrating lymphocytes with in vivo antitumor activity. J Biol Resp Mod 1990;9(2):149–59.Google Scholar
  33. 33.
    Barth RJ Mule JJ, Speiss PJ, et al. Interferon-gamma and tumor necrosis factor have a role in tumor regression mediated by murine CD8 + tumor infiltrating lymphocytes. J Exp Med 1991;173:647–58.PubMedGoogle Scholar
  34. 34.
    Anichini A, Mazzocchi A, Fossati G, Parmiani G. Cytotoxic T lymphocyte clones from peripheral blood and from tumor site detect intratumor heterogeneity of melanoma cells. Analysis of specificity and mechanisms of interaction. J Immunol 1989;142(10):3692–701.PubMedGoogle Scholar
  35. 35.
    Topalian SL, Solomon D, Rosenberg SA. Tumor-specific cytolysis by lymphocytes infiltrating human melanomas. J Immunol 1989;142(10):3714–25.PubMedGoogle Scholar
  36. 36.
    Van den Eynde BHP, Herin M, et al. Presence on a human melanoma of multiple antigens recognized by autologous CTL. Int J Cancer 1989;44:634–40.PubMedGoogle Scholar
  37. 37.
    Darrow TL, Slingluff CL, Jr., Seigler HF. The role of HLA class I antigens in recognition of melanoma cells by tumor-specific cytotoxic T lymphocytes. Evidence for shared tumor antigens. J Immunol 1989;142(9):3329–35.PubMedGoogle Scholar
  38. 38.
    Knuth A, Wolfel T, Klehmann E, Boon T, Meyer zum Buschenfelde KH. Cytolytic T-cell clones against an autologous human melanoma: specificity study and definition of three antigens by immunoselection. Proc Natl Acad Sci USA 1989;86(8):2804–8.PubMedGoogle Scholar
  39. 39.
    Townsend AR, Gotch FM, Davey J. Cytotoxic T cells recognize fragments of the influenza nucleoprotein. Cell 1985;42(2):457–67.PubMedGoogle Scholar
  40. 40.
    Townsend AR, Rothbard J, Gotch FM, Bahadur G, Wraith D, McMichael AJ. The epitopes of influenza nucleoprotein recognized by cytotoxic T lymphocytes can be defined with short synthetic peptides. Cell 1986;44(6):959–68.PubMedGoogle Scholar
  41. 41.
    Maryanski JL, Pala P, Corradin G, Jordan BR, Cerottini JC. H-2-restricted cytolytic T cells specific for HLA can recognize a synthetic HLA peptide. Nature 1986;324(6097):578–9.PubMedGoogle Scholar
  42. 42.
    Christinck ER, Luscher MA, Barber BH, Williams DB. Peptide binding to class I MHC on living cells and quantitation of complexes required for CTL lysis. Nature 1991;352(6330):67–70.PubMedGoogle Scholar
  43. 43.
    Rock KL, Gamble S, Rothstein L. Presentation of exogenous antigen with class I major histocompatibility complex molecules. Science 1990;249(4971):918–21.PubMedGoogle Scholar
  44. 44.
    Gilboa E, Nair SK, Lyerly HK. Immunotherapy of cancer with dendritic-cell-based vaccines. Cancer Immunol Immunother 1998;46(2):82–7.PubMedGoogle Scholar
  45. 45.
    Timmerman JM, Levy R. Dendritic cell vaccines for cancer immunotherapy. Annual review of medicine 1999;50:507–29.PubMedGoogle Scholar
  46. 46.
    Conrad C, Nestle FO. Dendritic cell-based cancer therapy. Curr Opin Mol Ther 2003;5(4):405–12.PubMedGoogle Scholar
  47. 47.
    Keilholz U, Weber J, Finke JH, et al. Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy. J Immunother 2002;25(2):97–138.PubMedGoogle Scholar
  48. 48.
    Cranmer LD, Trevor KT, Hersh EM. Clinical applications of dendritic cell vaccination in the treatment of cancer. Cancer Immunol Immunother 2004;53(4):275–306.PubMedGoogle Scholar
  49. 49.
    Hirschowitz EA, Foody T, Kryscio R, Dickson L, Sturgill J, Yannelli J. Autologous dendritic cell vaccines for non-small-cell lung cancer. J Clin Oncol 2004;22(14):2808–15.PubMedGoogle Scholar
  50. 50.
    Banchereau J, Briere F, Caux C, et al. Immunobiology of dendritic cells. Ann Rev Immunol 2000;18:767–811.Google Scholar
  51. 51.
    Germain RN. MHC-dependent antigen processing and peptide presentation: providing ligands for T lymphocyte activation. Cell 1994;76(2):287–99.PubMedGoogle Scholar
  52. 52.
    McAdam AJ, Schweitzer AN, Sharpe AH. The role of B7 co-stimulation in activation and differentiation of CD4 + and CD8 + T cells. Immunol Rev 1998;165:231–47.PubMedGoogle Scholar
  53. 53.
    Pulendran B, Smith JL, Caspary G, et al. Distinct dendritic cell subsets differentially regulate the class of immune response in vivo. Proc Natl Acad Sci USA 1999;96(3):1036–41.PubMedGoogle Scholar
  54. 54.
    Akbari O, DeKruyff RH, Umetsu DT. Pulmonary dendritic cells producing IL-10 mediate tolerance induced by respiratory exposure to antigen. Nat Immunol 2001;2(8):725–31.PubMedGoogle Scholar
  55. 55.
    Mayordomo JI, Zorina T, Storkus WJ, et al. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat Med 1995;1(12):1297–302.PubMedGoogle Scholar
  56. 56.
    Boczkowski D, Nair SK, Snyder D, Gilboa E. Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J Exp Med 1996;184(2):465–72.PubMedGoogle Scholar
  57. 57.
    Flamand V, Sornasse T, Thielemans K, et al. Murine dendritic cells pulsed in vitro with tumor antigen induce tumor resistance in vivo. Eur J Immunol 1994;24(3):605–10.PubMedGoogle Scholar
  58. 58.
    Porgador A, Gilboa E. Bone marrow-generated dendritic cells pulsed with a class I-restricted peptide are potent inducers of cytotoxic T lymphocytes. J Exp Med 1995;182(1):255–60.PubMedGoogle Scholar
  59. 59.
    Coveney E, Wheatley GH, 3rd, Lyerly HK. Active immunization using dendritic cells mixed with tumor cells inhibits the growth of primary breast cancer. Surgery 1997;122(2):228–34.PubMedGoogle Scholar
  60. 60.
    Small EJ, Sacks N, Nemunaitis J, et al. Granulocyte macrophage colony-stimulating factor--secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer. Clin Cancer Res 2007;13(13):3883–91.PubMedGoogle Scholar
  61. 61.
    Ribas A. Genetically modified dendritic cells for cancer immunotherapy. Curr Gene Ther 2005;5(6):619–28.PubMedGoogle Scholar
  62. 62.
    Nemunaitis J, Dillman RO, Schwarzenberger PO, et al. Phase II study of belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer. J Clin Oncol 2006;24(29):4721–30.PubMedGoogle Scholar
  63. 63.
    Sporn MB, Roberts AB, Wakefield LM, Assoian RK. Transforming growth factor-beta: biological function and chemical structure. Science 1986;233(4763):532–4.PubMedGoogle Scholar
  64. 64.
    Massague J. The TGF-beta family of growth and differentiation factors. Cell 1987;49(4):437–8.PubMedGoogle Scholar
  65. 65.
    Border WA, Ruoslahti E. Transforming growth factor-beta in disease: the dark side of tissue repair. J Clin Invest 1992;90(1):1–7.PubMedGoogle Scholar
  66. 66.
    Bodmer S, Strommer K, Frei K, et al. Immunosuppression and transforming growth factor-beta in glioblastoma. Preferential production of transforming growth factor-beta 2. J Immunol 1989;143(10):3222–9.PubMedGoogle Scholar
  67. 67.
    Jakowlew SB, Mathias A, Chung P, Moody TW. Expression of transforming growth factor beta ligand and receptor messenger RNAs in lung cancer cell lines. Cell Growth Differ 1995;6(4):465–76.PubMedGoogle Scholar
  68. 68.
    Constam DB, Philipp J, Malipiero UV, ten Dijke P, Schachner M, Fontana A. Differential expression of transforming growth factor-beta 1, -beta 2, and -beta 3 by glioblastoma cells, astrocytes, and microglia. J Immunol 1992;148(5):1404–10.PubMedGoogle Scholar
  69. 69.
    Kong F, Jirtle RL, Huang DH, Clough RW, Anscher MS. Plasma transforming growth factor-beta1 level before radiotherapy correlates with long term outcome of patients with lung carcinoma. Cancer 1999;86(9):1712–9.PubMedGoogle Scholar
  70. 70.
    Ruffini PA, Rivoltini L, Silvani A, Boiardi A, Parmiani G. Factors, including transforming growth factor beta, released in the glioblastoma residual cavity, impair activity of adherent lymphokine-activated killer cells. Cancer Immunol Immunother 1993;36(6):409–16.PubMedGoogle Scholar
  71. 71.
    Kasid A, Bell GI, Director EP. Effects of transforming growth factor-beta on human lymphokine-activated killer cell precursors. Autocrine inhibition of cellular proliferation and differentiation to immune killer cells. J Immunol 1988;141(2):690–8.PubMedGoogle Scholar
  72. 72.
    Hirte H, Clark DA. Generation of lymphokine-activated killer cells in human ovarian carcinoma ascitic fluid: identification of transforming growth factor-beta as a suppressive factor. Cancer Immunol Immunother 1991;32(5):296–302.PubMedGoogle Scholar
  73. 73.
    Naganuma H, Sasaki A, Satoh E, et al. Transforming growth factor-beta inhibits interferon-gamma secretion by lymphokine-activated killer cells stimulated with tumor cells. Neurol Med Chir (Tokyo) 1996;36(11):789–95.Google Scholar
  74. 74.
    Fakhrai H, Mantil JC, Liu L, et al. Phase I clinical trial of a TGF-beta antisense-modified tumor cell vaccine in patients with advanced glioma. Cancer gene therapy 2006;13(12):1052–60.PubMedGoogle Scholar
  75. 75.
    Liau LM, Fakhrai H, Black KL. Prolonged survival of rats with intracranial C6 gliomas by treatment with TGF-beta antisense gene. Neurol Res 1998;20(8):742–7.PubMedGoogle Scholar
  76. 76.
    Kettering JD, Mohamedali AM, Green LM, Gridley DS. IL-2 gene and antisense TGF-beta1 strategies counteract HSV-2 transformed tumor progression. Technol Cancer Res Treat 2003;2(3):211–21.PubMedGoogle Scholar
  77. 77.
    Fakhrai H, Dorigo O, Shawler DL, et al. Eradication of established intracranial rat gliomas by transforming growth factor beta antisense gene therapy. Proc Natl Acad Sci USA 1996;93(7):2909–14.PubMedGoogle Scholar
  78. 78.
    Dorigo O, Shawler DL, Royston I, Sobol RE, Berek JS, Fakhrai H. Combination of transforming growth factor beta antisense and interleukin-2 gene therapy in the murine ovarian teratoma model. Gynecol Oncol 1998;71(2):204–10.PubMedGoogle Scholar
  79. 79.
    Tzai TS, Shiau AL, Liu LL, Wu CL. Immunization with TGF-beta antisense oligonucleotide-modified autologous tumor vaccine enhances the antitumor immunity of MBT-2 tumor-bearing mice through upregulation of MHC class I and Fas expressions. Anticancer Res 2000;20(3A):1557–62.PubMedGoogle Scholar
  80. 80.
    Tzai TS, Lin CI, Shiau AL, Wu CL. Antisense oligonucleotide specific for transforming growth factor-beta 1 inhibit both in vitro and in vivo growth of MBT-2 murine bladder cancer. Anticancer Res 1998;18(3A):1585–9.PubMedGoogle Scholar
  81. 81.
    Marzo AL, Fitzpatrick DR, Robinson BW, Scott B. Antisense oligonucleotides specific for transforming growth factor beta2 inhibit the growth of malignant mesothelioma both in vitro and in vivo. Cancer research 1997;57(15):3200–7.PubMedGoogle Scholar
  82. 82.
    Park JA, Wang E, Kurt RA, Schluter SF, Hersh EM, Akporiaye ET. Expression of an antisense transforming growth factor-beta1 transgene reduces tumorigenicity of EMT6 mammary tumor cells. Cancer Gene Therapy 1997;4(1):42–50.PubMedGoogle Scholar
  83. 83.
    Hege KM, Carbone DP. Lung cancer vaccines and gene therapy. Lung Cancer 2003;41(Suppl 1):S103–13.PubMedGoogle Scholar
  84. 84.
    Nemunaitis J, Sterman D, Jablons D, et al. Granulocyte-macrophage colony-stimulating factor gene-modified autologous tumor vaccines in non-small-cell lung cancer. J Natl Cancer Inst 2004;96(4):326–31.PubMedGoogle Scholar
  85. 85.
    Nemunaitis J, Vorhies JS, Pappen B, Senzer N. 10-year follow-up of gene-modified adenoviral-based therapy in 146 non-small-cell lung cancer patients. Cancer Gene Therapy 2007;14(8):762–3.PubMedGoogle Scholar
  86. 86.
    Nemunaitis J, Jahan T, Ross H, et al. Phase 1/2 trial of autologous tumor mixed with an allogeneic GVAX vaccine in advanced-stage non-small-cell lung cancer. Cancer Gene Therapy 2006;13(6):555–62.PubMedGoogle Scholar
  87. 87.
    Mueller-Pillasch F, Pohl B, Wilda M, et al. Expression of the highly conserved RNA binding protein KOC in embryogenesis. Mech Dev 1999;88(1):95–9.PubMedGoogle Scholar
  88. 88.
    Aguiar JC, Hedstrom RC, Rogers WO, et al. Enhancement of the immune response in rabbits to a malaria DNA vaccine by immunization with a needle-free jet device. Vaccine 2001;20(1–2):275–80.PubMedGoogle Scholar
  89. 89.
    Nemunaitis J, Meyers T, Senzer N, et al. Phase I Trial of sequential administration of recombinant DNA and adenovirus expressing L523S protein in early stage non-small-cell lung cancer. Mol Ther 2006;13(6):1185–91.PubMedGoogle Scholar
  90. 90.
    Antonia SJ, Seigne J, Diaz J, et al. Phase I trial of a B7–1 (CD80) gene modified autologous tumor cell vaccine in combination with systemic interleukin-2 in patients with metastatic renal cell carcinoma. J Urol 2002;167(5):1995–2000.PubMedGoogle Scholar
  91. 91.
    Horig H, Lee DS, Conkright W, et al. Phase I clinical trial of a recombinant canarypoxvirus (ALVAC) vaccine expressing human carcinoembryonic antigen and the B7.1 co-stimulatory molecule. Cancer Immunol Immunother 2000;49(9):504–14.PubMedGoogle Scholar
  92. 92.
    Hull GW, McCurdy MA, Nasu Y, et al. Prostate cancer gene therapy: comparison of adenovirus-mediated expression of interleukin 12 with interleukin 12 plus B7–1 for in situ gene therapy and gene-modified, cell-based vaccines. Clin Cancer Res 2000;6(10):4101–9.PubMedGoogle Scholar
  93. 93.
    Mehren M, Arlen P, Tsang KY, et al. Pilot study of a dual gene recombinant avipox vaccine containing both carcinoembryonic antigen (CEA) and B7.1 transgenes in patients with recurrent CEA-expressing adenocarcinomas. Clin Cancer Res 2000;6(6):2219–28.Google Scholar
  94. 94.
    Johnston JV, Malacko AR, Mizuno MT, et al. B7-CD28 costimulation unveils the hierarchy of tumor epitopes recognized by major histocompatibility complex class I-restricted CD8 + cytolytic T lymphocytes. J Experiment Med 1996;183(3):791–800.Google Scholar
  95. 95.
    Liu B, Podack ER, Allison JP, Malek TR. Generation of primary tumor-specific CTL in vitro to immunogenic and poorly immunogenic mouse tumors. J Immunol 1996;156(3):1117–25.PubMedGoogle Scholar
  96. 96.
    Nabel GJ, Gordon D, Bishop DK, et al. Immune response in human melanoma after transfer of an allogeneic class I major histocompatibility complex gene with DNA-liposome complexes. Proc Natl Acad Sci USA 1996;93(26):15388–93.PubMedGoogle Scholar
  97. 97.
    Raez LE, Cassileth PA, Schlesselman JJ, et al. Allogeneic vaccination with a B7.1 HLA-A gene-modified adenocarcinoma cell line in patients with advanced non-small-cell lung cancer. J Clin Oncol 2004;22(14):2800–7.PubMedGoogle Scholar
  98. 98.
    Raez LE, Santos ES, Mudad R, Podack ER. Clinical trials targeting lung cancer with active immunotherapy: the scope of vaccines. Expert Rev Anticancer Ther 2005;5(4):635–44.PubMedGoogle Scholar
  99. 99.
    Link CJ, Jr., Seregina T, Atchison R, Hall A, Muldoon R, Levy JP. Eliciting hyperacute xenograft response to treat human cancer: alpha(1,3) galactosyltransferase gene therapy. Anticancer Res 1998;18(4A):2301–8.PubMedGoogle Scholar
  100. 100.
    Morris JC, Vahan ian, N., and Janik, J.E. Phase I study of an antitumor vaccination using α(1,3)galactosyltransferase expressing allogeneic tumor cells in patients (Pts) with refractory or recurrent non-small cell lung cancer (NSCLC). J Clini Oncol, 2005 ASCO Annual Meeting Proceedings 2005;23(No. 16S, Part I of II (June 1 Supplement)):2586.Google Scholar
  101. 101.
    Ten Have-Opbroek AA, Benfield JR, Hammond WG, Teplitz RL, Dijkman JH. In favour of an oncofoetal concept of bronchogenic carcinoma development. Histol Histopathol 1994;9(2):375–84.PubMedGoogle Scholar
  102. 102.
    Toloza EM, Roth JA, Swisher SG. Molecular events in bronchogenic carcinoma and their implications for therapy. Semin Surg Oncol 2000;18(2):91–9.PubMedGoogle Scholar
  103. 103.
    Ihde DC, Minna JD. Non-small cell lung cancer. Part I: Biology, diagnosis, and staging. Curr Probl Cancer 1991;15(2):61–104.PubMedGoogle Scholar
  104. 104.
    Salgia R, Lynch T, Skarin A, et al. Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor augments antitumor immunity in some patients with metastatic non-small-cell lung carcinoma J Clin Oncol 2003;21(4):624–30.Google Scholar

Copyright information

© Humana Press, a part of Springer Science+Business Media, LLC 2009

Authors and Affiliations

  1. 1.Mary Crowley Cancer Research CenterDallasTX

Personalised recommendations